CNMD - CONMED Corporation
| Previous Close | 110.73 |
| Open | 111.21 |
| Bid | 95.00 x 1200 |
| Ask | 110.57 x 900 |
| Day's Range | 110.13 - 111.22 |
| 52 Week Range | 63.01 - 116.81 |
| Volume | 135,622 |
| Avg. Volume | 248,893 |
| Market Cap | 3.136B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | 109.85 |
| EPS (TTM) | 1.01 |
| Earnings Date | Jan 28, 2020 |
| Forward Dividend & Yield | 0.80 (0.72%) |
| Ex-Dividend Date | Dec 10, 2019 |
| 1y Target Est | 125.20 |
- Business Wire
CONMED Corporation to Announce Fourth Quarter and Full-Year 2019 Financial Results on January 29, 2020
CONMED Corporation (NASDAQ: CNMD) today announced that it will report financial results for the fourth quarter and full year 2019 after the market close on Wednesday, January 29, 2020. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.
- Investor's Business Daily
Stocks To Watch Ahead Of Earnings: ConMed
With earnings on tap for Jan. 20, ConMed is currently approximately 4% below a 116.91 buy point. The pattern is a second-stage flat base. Keep in mind that jumping into a stock right as it gets ready to report means you likely won't have enough time to build a profit cushion before the release.
- Business Wire
CONMED Corporation to Present at the J.P. Morgan Healthcare Conference
CONMED Corporation (NASDAQ: CNMD) today announced that Curt R. Hartman, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PT on Monday, January 13, 2020 in San Francisco, CA.
- Zacks
Here's Why You Should Invest in Patterson Companies Stock Now
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts.
- Zacks
Here's Why You Should Retain Pacific Biosciences Stock Now
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
- Zacks
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
- Zacks
HMS Holdings Acquires Nebraska-Based Intrado's Accent Unit
The latest deal is likely to boost HMS Holdings' (HMSY) Payment Integrity solutions business.
- Zacks
Here's Why You Should Hold on to Masimo (MASI) Stock Now
Masimo (MASI) raises revenue and earnings guidance for 2019.
- Zacks
PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?
PDCO vs. CNMD: Which Stock Is the Better Value Option?
- Zacks
6 MedTech Stocks That are Set to Beat the Market in 2020
Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.
- Zacks
Masimo (MASI) Expands Partnership with Texas-Based Drager
Masimo (MASI) sees a slew of developments in recent times.
- Zacks
Hill-Rom (HRC) Rides on International Growth, New Launches
Hill-Rom (HRC) launches RetinaVue 700 Imager, EarlySense and WatchCare in 2019.
- Zacks
LHC Group Expands Partnership With Ochsner Health System
LHC Group (LHCG) sees major expansion in partnerships of late.
- Simply Wall St.
Should You Be Concerned About CONMED Corporation's (NASDAQ:CNMD) ROE?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Zacks
Here's Why You Should Add DexCom (DXCM) to Your Portfolio
DexCom (DXCM) raises its 2019 revenue and EPS guidance.
- Zacks
Here's Why You Should Hold on to Allscripts Stock for Now
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
- Zacks
Here's Why You Should Bet on Integer Holdings Stock Now
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
- Zacks
LHC Group Expands Partnership With Tennessee-Based Medalogix
Management at LHC Group (LHCG) expects to complete the expansion by the first quarter of 2020.
- Zacks
Here's Why You Should Invest in Cardinal Health Stock Now
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
- Zacks
McKesson, Walgreens Form JV for European Pharmaceutical Unit
The VA selects McKesson (MCK) as their prime pharmaceutical supplier.
- Zacks
NextGen Healthcare Boosts Patient Care With CHC Strategies
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
- Zacks
LHC Group Set to Gain From Expansion of LifePoint Health JV
LHC Group (LHCG) expects approximately $5.4 million in annualized revenues from this transaction.
- Zacks
Are You Looking for a Top Momentum Pick? Why Conmed (CNMD) is a Great Choice
Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
Here's Why You Should Retain NextGen Healthcare for Now
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
- Zacks
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
Ecolab (ECL) slashes 2019 EPS view owing to foreign exchange headwinds.
